173
Participants
Start Date
December 18, 2014
Primary Completion Date
April 6, 2021
Study Completion Date
April 6, 2022
Imatinib (Stopping their TKI)
Patients with CML on treatment with imatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
Dasatinib (Stopping their TKI)
Patients with CML on treatment with dasatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
Nilotinib (Stopping their TKI)
Patients with CML on treatment with nilotinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
Bosutinib (Stopping their TKI)
Patients with CML on treatment with bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
Weill Medical College of Cornell University, New York
Memorial Sloan Kettering Cancer Center, New York
Roswell Park Cancer Institute, Buffalo
Duke University Medical Center, Durham
Winship Cancer Institute of Emory University, Atlanta
Moffit Cancer Center, Tampa
Karmanos Cancer Institute of Wayne State University, Detroit
Froedtert Hospital & Medical College of Wisconsin, Milwaukee
The University of Chicago Medicine Comprehensive Cancer Center at Silver Cross, New Lenox
The University of Chicago, Chicago
MD Anderson Cancer Center, Houston
Helen Diller Family Comprehensive Cancer Center University of California, San Francisco
Beth Israel Deaconess Medical Center (Satellite site of Dana Farber), Boston
Dana Farber Cancer Institute, Boston
University of Utah Huntsman Cancer Institute, Salt Lake City
Fred Hutchinson Cancer Research Center, Seattle
University of Chicago
OTHER
University of California, San Francisco
OTHER
University of Utah
OTHER
Dana-Farber Cancer Institute
OTHER
Emory University
OTHER
Barbara Ann Karmanos Cancer Institute
OTHER
Duke Cancer Institute
OTHER
Fred Hutchinson Cancer Center
OTHER
Memorial Sloan Kettering Cancer Center
OTHER
Weill Medical College of Cornell University
OTHER
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Medical College of Wisconsin
OTHER